Language selection

Search

Patent 1166259 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 1166259
(21) Application Number: 386516
(54) English Title: ANTITUMOR AND IMMUNOSUPPRESSIVE 4-CARBAMOYL IMIDAZOLIUM-5-OLATE DERIVATIVES, PHARMACEUTICAL COMPOSITION, PRODUCTION AND USE THEREOF
(54) French Title: DERIVES DE 4-CARBAMOYL IMIDAZOLIUM-5-OLATE, ANTI- TUMEURS ET IMMUNOSUPPRESSEURS; COMPOSITION PHARMACEUTIQUE, PREPARATION ET APPLICATIONS
Status: Expired
Bibliographic Data
(52) Canadian Patent Classification (CPC):
  • 260/305
  • 260/314
(51) International Patent Classification (IPC):
  • C07D 233/90 (2006.01)
(72) Inventors :
  • KIYOHARA, TAKAO (Japan)
  • SANJIKI, TETSUTARO (Japan)
  • ATSUMI, TOSHIO (Japan)
(73) Owners :
  • SUMITOMO CHEMICAL COMPANY, LIMITED (Japan)
(71) Applicants :
(74) Agent: RIDOUT & MAYBEE LLP
(74) Associate agent:
(45) Issued: 1984-04-24
(22) Filed Date: 1981-09-23
Availability of licence: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): No

(30) Application Priority Data: None

Abstracts

English Abstract





Abstract of the Disclosure
There are provided compounds of the
formula:
Image
wherein R is a mono-substituted benzoyl group which is
substituted with a phenyl group, an alkanoyl group,
a formyl group, a halogeno-alkyl group, an aralkyloxy
group, a phenoxy group, an alkoxycarbonyl group, an aral-
kyloxycarbonyl group, an alkanoyloxy group, a benzoyl
group, a carboxyl group, a hydroxy group, a group of the
formula:
Image
(wherein X1 and X2 are a hydrogen atom or u lower alkyl
group), an aralkyloxycarbonylamino group, a lower alkoxy-
carbonylamino group, a carboxyamino group or a carbamoyl
group; a cinnamoyl group which may be substituted at
a position or the phenyl ring with an alkyl group, an
alkoxy group, an aryl group, a nitro group, a methylene-
dioxy group, a formyl group, a halogeno-alkyl group,
a halogen atom, a hydroxy group, a carboxyl group, an
amino group or a cyano group; or a benzoyl group substi-
tuted with from two to five of the same or different
substituents selected from the group consisting of alkyl
groups, alkoxy groups, aralkyloxy groups, nitro group,
halogen atoms, hydroxy group, alkanoyloxy groups, formyl



group, carboxy group, alkylthio groups, alkylsulfonyl
groups, groups of the formula:
Image
(wherein X1 and X2 are a hydrogen atom or a lower alkyl
group), sulfo group and sulfamoyl group; or its non-toxic
salt, and a process for producing them.
The compounds are useful as antitumor agents and
immunosuppressants.


Claims

Note: Claims are shown in the official language in which they were submitted.


THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. A process for producing a compound of formula I:
Image
wherein R is a mono-substituted benzoyl group which is
substituted with a phenyl group, an alkanoyl group, a
formyl group, a halogeno-alkyl group, an aralkyloxy group,
a phenoxy group, an alkoxycarbonyl group, an aralkyloxy-
carbonyl group, an alkanoyloxy group, a benzoyl group, a
carboxyl group, a hydroxy group, a group of the formula:
Image
(wherein X1 and X2 are a hydrogen atom or a lower alkyl
group), an aralkyloxycarbonylamino group, a lower alkoxy-
carbonylamino group, a carboxyamino group or a carbamoyl
group; a cinnamoyl group which may be substituted at a
position or the phenyl ring with an alkyl group, an alkoxy
group, an aryl group, a nitro group, a methylene-dioxy
group, a formyl group, a halogeno-alkyl group, a halogen
atom, a hydroxy group, a carboxyl group, an amino group or
a cyano group; or a benzoyl group substituted with from
two to five of the same or different substituents selected
from the group consisting of alkyl groups, alkoxy groups,
aralkyloxy groups, nitro group, halogen atoms, hydroxy
group, alkanoyloxy groups, formyl group, carboxyl group,
alkylthio groups, alkylsulfonyl groups, groups of the
formula:
Image


(wherein X1 and X2 are a hydrogen atom or a lower alkyl
group), sulfo group and sulfamoyl group; or its non-toxic
salt, which process comprises reacting 4-carbamoylimidazolium-
5-olate of the formula,
Image
or its obvious chemical equivalent with a carboxylic acid
or its obvious chemical equivalent of the formula,
R - OH
wherein R is as defined above.
2. A process according to Claim 1, wherein R is a
mono-substituted benzoyl group which is substituted with a
phenyl group, an alkanoyl group, a formyl group, a halogeno-
alkyl group, an aralkyloxy group, a phenoxy group, an
alkoxycarbonyl group, aralkyloxycarbonyl group, an alkanoyl-
oxy group, a benzoyl group, a carboxyl group, a hydroxy
group, a group of the formula:
Image
(wherein X1 and X2 are a hydrogen atom or a lower alkyl
group), an aralkyloxycarbonylamino group, a lower alkoxy-
carbonylamino group, a carboxyamino group or a carbamoyl
group.
3. A process according to Claim 1, wherein R is a
cinnamoyl group which may be substituted at an a position
or phenyl ring with an alkyl group, an alkoxy group, an
aryl group, a nitro group, a methylenedioxy group, a formyl
group, a halogeno-alkyl group, a halogen atom, a hydroxy
group, a carboxyl group, an amino group or a cyano group.

26

4. A process according to Claim 1, wherein R is a
benzoyl group substituted with from two to five of the same
or different substituents selected from the group consisting
of alkyl groups, alkoxy groups, aralkyloxy groups, nitro
group, halogen atoms, hydroxy group, alkanoyloxy groups,
formyl group, carboxyl group, alkylthio groups, alkylsul-
fonyl groups, groups of the formula:
Image
(wherein X1 and X2 are a halogen atom or a lower alkyl group),
sulfo group and sulfamoyl group.
5. A process according to Claim 2, wherein R is
p-benzyloxybenzoyl.
6. A process according to Claim 2, wherein R is
m-trifluoromethylbenzoyl.
7. A process according to Claim 2, wherein R is
p-N-benzyloxycarbonylaminobenzoyl.
8. A process according to Claim 2, wherein R is
4-biphenylylcarbonyl.
9. A process according to Claim 2, wherein R is
o-acetylsalicyloyl.
10. A process according to Claim 2, wherein R is
o-benzyloxycarbonylbenzoyl.
11. A process according to Claim 2, wherein R is
p-methoxycarbonylbenzoyl.
12. A process according to Claim 3, wherein R is
cinnamoyl.
13. A process according to Claim 3, wherein R is
p-methylcinnamoyl.
14. A process according to Claim 3, wherein R is
p-chlorocinnamoyl.

27

15. A process according to Claim 3, wherein R is
3,4-methylenedioxycinnamoyl.

16. A process according to Claim 3, wherein R is
p-methoxycinnamoyl.

17. A process according to Claim 3, wherein R is
p-formylcinnamoyl.

18. A process according to Claim 3, wherein R is
m-trifluoromethylcinnamoyl.

19. A process according to Claim 3, wherein R is
m-nitrocinnamoyl.

20. A process according to Claim 3, wherein R is
a-phenylcinnamoyl.

21. A process according to Claim 4, wherein R is
2,6-dimethylbenzoyl.

22. A process according to Claim 4, wherein R is
3,4-dimethoxybenzoyl.

23. A process according to Claim 4, wherein R is
2,4,6-trimethoxybenzoyl.

24. A process according to Claim 4, wherein R is
3,4-bisbenzyloxybenzoyl.

25. A process according to Claim 4, wherein R is
3,4-dihydroxybenzoyl.


26. A process according to Claim 4, wherein R is
3,5-dinitrobenzoyl.

27. A process according to Claim 4, wherein R is
3-methoxy-4-methylbenzoyl.

28


28. A compound of formula I:
Image
wherein R is a mono-substituted benzoyl group which is
substituted with a phenyl group, an alkanoyl group, a
formyl group, a halogeno-alkyl group, an aralkyloxy
group, a phenoxy group, an alkoxycarbonyl group, an
aralkyloxycarbonyl group, an alkanoyloxy group, a benzoyl
group, a carboxyl group, a hydroxy group, a group of the
formula:
Image
(wherein X1 and X2 are a hydrogen atom or a lower alkyl
group), an aralkyloxycarbonylamino group, a lower alkoxy-
carbonylamino group, a carboxyamino group or a carbamoyl
group; a cinnamoyl group which may be substituted at a
position or the phenyl ring with an alkyl group, an alkoxy
group, an aryl group, a nitro group, a methylenedioxy group,
a formyl group, a halogeno-alkyl group, a halogen atom, a
hydroxy group, a carboxyl group, an amino group or a cyano
group; or a benzoyl group substituted with from two to five
of the same or different substituents selected from the
group consisting of alkyl groups, alkoxy groups, aralkyloxy
groups, nitro group, halogen atoms, hydroxy group, alkanoy-
loxy groups, formyl group, carboxyl group, alkylthio groups,
alkylsulfonyl groups, groups of the formula:
Image

29


(wherein X1 and X2 are a hydrogen atom or a lower alkyl
group), sulfo group and sulfamoyl group; or its non-toxic
salt, when produced by the process of claim 1 or by its
obvious chemical equivalents.
29. A compound of formula I, wherein R is a mono-
substituted benzoyl group which is substituted with a
phenyl group, an alkanoyl group, a formyl group, a halogeno-
alkyl group, an aralkyloxy group, a phenoxy group, an alk-
oxycarbonyl group, aralkyloxycarbonyl group, an alkanoyloxy
group, a benzoyl group, a carboxyl group, a hydroxy group,
a group of the formula:
Image
(wherein X1 and X2 are hydrogen atom or a lower alkyl
group), an aralkyloxycarbonylamino group, a lower alkoxy-
carbonylamino group, a carboxyamino group or a carbamoyl
group, when produced by the process of claim 2 or by its
obvious chemical equivalents.
30. A compound of formula I, wherein R is a cinnamoyl
group which may be substituted at a .alpha. position or phenyl
ring with an alkyl group, an alkoxy group, an aryl group,
a nitro group, a methylenedioxy group, a formyl group, a
halogeno-alkyl group, a halogen atom, a hydroxy group, a
carboxyl group, an amino group or a cyano group, when pro-
duced by the process of claim 3 or by its obvious chemical
equivalents.
31. A compound of formula I, wherein R is a benzoyl
group substituted with from two to five of the same or



different substituents selected from the group consisting
of alkyl groups, alkoxy groups, aralkyloxy groups, nitro
group, halogen atoms, hydroxy group, alkanoyloxy groups,
formyl group, carboxyl group, alkylthio groups, alkylsul-
fonyl groups, groups of the formula:
Image
(wherein X1 and X2 are a halogen atom or a lower alkyl
group), sulfo group and sulfamoyl group, when produced by
the process of claim 4 or by its obvious chemical equivalents.
32. A compound of formula I, wherein R is p-benzyloxy-
benzoyl, when produced by the process of claim 5 or by its
obvious chemical equivalents.
33. A compound of formula I, wherein R is m-trifluoro-
methylbenzoyl, when produced by the process of claim 6 or
by its obvious chemical equivalents.
34. A compound of formula I, wherein R is p-N-benzyl-
oxycarbonylaminobenzoyl, when produced by the process of
claim 7 or by its obvious chemical equivalents.
35. A compound of formula I, wherein R is 4-biphenyl-
ylcarbonyl, when produced by the process of claim 8 or by
its obvious chemical equivalents.
36. A compound of formula I, wherein R is o-acetyl-
salicyloyl, when produced by the process of claim 9 or by
its obvious chemical equivalents.
37. A compound of formula I, wherein R is o-benzyl-
oxycarbonylbenzoyl, when produced by the process of claim
10 or by its obvious chemical equivalents.

31



38. A compound of formula I, wherein R is p-methoxy-
carbonylbenzoyl, when produced by the process of claim 11
or by its obvious chemical equivalents.
39. A compound of formula I, wherein R is cinnamoyl,
when produced by the process of claim 12 or by its obvious
chemical equivalents.
40. A compound of formula I, wherein R is p-methyl-
cinnamoyl, when produced by the process of claim 13 or by
its obvious chemical equivalents.
41. A compound of formula I, wherein R is p-chloro-
cinnamoyl, when produced by the process of claim 14 or by
its obvious chemical equivalents.
42. A compound of formula I, wherein R is 3,4-methy-
lenedioxycinnamoyl, when produced by the process of claim
15 or by its obvious chemical equivalents.
43. A compound of formula I, wherein R is p-methoxy-
cinnamoyl, when produced by the process of claim 16 or by
its obvious chemical equivalents.
44. A compound of formula I, wherein R is p-formyl-
cinnamoyl, when produced by the process of claim 17 or by
its obvious chemical equivalents.
45. A compound of formula I, wherein R is m-trifluoro-
methylcinnamoyl, when produced by the process of claim 18
or by its obvious chemical equivalents.
46. A compound of formula I, wherein R is m -nitro-
cinnamoyl, when produced by the process of claim 19 or by
its obvious chemical equivalents.

32


47. A compound of formula I, wherein R is a-phenyl-
cinnamoyl, when produced by the process of claim 20 or by
its obvious chemical equivalents.
48. A compound of formula I, wherein R is 2,6-dimethyl-
benzoyl, when produced by the process of claim 21 or by its
obvious chemical equivalents.
49. A compound of formula I, wherein R is 3,4-dimeth-
oxybenzoyl, when produced by the process of claim 22 or by
its obvious chemical equivalents.
50. A compound of formula I, wherein R is 2,4,6-tri-
methoxybenzoyl, when produced by the process of claim 23
or by its obvious chemical equivalents.
51. A compound of formula I, wherein R is 3,4-bis-
benzyloxybenzoyl, when produced by the process of claim 24
or by its obvious chemical equivalents.
52. A compound of formula I, wherein R is 3,4-dihydro-
xybenzoyl, when produced by the process of claim 25 or by
its obvious chemical equivalents.
53. A compound of formula I, wherein R is 3,5-dinitro-
benzoyl, when produced by the process of claim 26 or by its
obvious chemical equivalents.
54. A compound of formula I, wherein R is 3-methoxy-
4-methylbenzoyl, when produced by the process of claim 27
or by its obvious chemical equivalents.

33

Description

Note: Descriptions are shown in the official language in which they were submitted.


D ~




The present invention relates to novel
4-carbamoylimidazolium-5-olate derivatives and a process
for preparing them. ~ore particularly, the present
invention pertains to 4-carbamoylimidazolium-5-olate
deriva-tives useful as antitumor agents and immunosup-
pressants, a pharmaceutical composition containing at
least one of them, and a process for preparing them.
~ he no~el imidazole derivatives of the present
invention are those represented b~ the following formula (I),

H2N - C 1I NH
~ ~ (I)

wherein R is a mono-substituted benzoyl group which is
substituted with a phenyl group, an alkanoyl group,
a formyl group, a halogeno-alkyl group9 an aralk~lox~
group, a phenoxy group, an alkoxycarbonyl group, an
aralkyloxycarbonyl group, an alkanoylox~ group, a ben~oyl
group, a carboxyl group~ a hydroxy group, a group of the
formula:
/X
- N \
X2
(wherein Xl and X2 are a hydrogen atom or lower alkyl
group), an aralkylox~carbonylamino group, a lower alkoxy-
carbonylamino group, a carboxyamino group or a carbamoyl
group; a cinnamoyl group which may be substituted at
a positio~ or the phenyl ring with an alkyl group, an
alkoxy group, an aryl group, a nitro group, a methylene-
dioxy group, a form~l group 3 a halogeno-alkyl group,

_
'




a halogen atom, a hydroxy group, a carboxyl group, an
amino group or a cyano group; or a benzoyl group substi-
tuted with from two to five of the same or dif~erent
substituents selected from the group con~isting of alkyl
groups, alkoxy groups, aralkyloxy groups, nitro group,
halogen atoms, hydroxy group, alkanoyloxy groups, formyl
group, carboxyl group, alkylthio groups, alkylsulfonyl
groups, groups of the formula:

N~ ~1
~X2
(wherein Xl and X2 are a hydrogen atom or a lower alkyl
group), sulfo group and sulfamoyl group, or its non-toxic
salt.
As used herein, the term "alkanoyl" means lower
alkanoyl having 2 to 6 carbon atoms (e.g. acetyl, propionyl,
pivaloyl hexanoyl), medium alkanoyl having 7 to 12 carbon
atoms (e.g. lauroyl) and higher alkanoyl having 13 to ?2
carbon atoms (e.g. octanoyl, palmitoyl).
The term "halogeno-alkyl" mean~ lower alkyl having
1 to 6 carbon atoms substituted with the following halogen
atom (e.g. trifluoromethyl, ~-chloroethyl).
~he term "aralkyloxy" means lower alkoxy having
1 to 6 carbon atoms substituted with an aryl group such as
benzyloxy, a-methylbenzyloxy, phenethyloxy and the llke.
The term "alkoxycarbonyl" means lower alkoxy
carbonyl having 2 to 7 carbon atoms (e.g. methoxycarbonyl,
ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl),
mediwm alkoxycarbonyl having 8 to 13 carbon atom~ (e.g.
octyloxycarbonyl) and higher alkoxycarbonyl having 14 to

s~


23 carbon atoms (e.g. octadecyloxycarbonyl, docosyloxy-
carbonyl).
The term "aralkyloxycarbonyl" means a carbonyl
substituted with the above aralkyloxy group (e.g. ben~yloxy-
carbonyl, a-methylbenzyloxycarbonyl, phenethyloxycarbonyl
and the like~.
The term "alkanoyloxy" means lower alkanoyloxy
having 2 to 6 carbon atoms (e.g. acetoxy, propionyloxy,
pivaloyloxy, hexanoyloxy), medium alkanoyloxy having 7 to
12 carbon atoms (e.g. octanoyloxy, lauroyloxy) and higher
alkanoyloxy having 13 to 22 carbon atoms (e.g. palmitoyloxy,
stearoyloxy).
The term "aralkyloxycarbonylaminol- means an amino
group substituted with the above aralkyloxycarbonyl group.
The term 'llower alkoxycarbonylamino" means an
amino group substituted with the above lower alkoxycarbonyl
group.
The term "alkyl" means lower alkyl having 1 to 6
carbon atoms (e.g. methyl, ethyl, n-propyl, iso-propyl,
n-butyl, isobutyl, t-butyl, hexyl), medium alkyl having
7 to 12 carbon atoms (e.g. octyl, decyl, dodecyl) ana higher
alkyl having 13 to 22 carbon atoms (e.g. pentadecyl? docosyl).
The term "alkoxy" means lower aIkoxy having 1 to 6
carbon atom (e.g. methoxy, ethoxy, n-propoxy, isopropoxy,
n-butoxy, isobutoxy), medium alkoxy having 7 to 12 carbon
atoms (e.g. octyloxy, dodecyloxy) and higher alkoxy having
13 to 22 carbon atoms (e.g. octadecyloxy, docosyloxy).
The term "aryl" means ~uch as phenyl, tolyl,
naphtyl and the like.



.

;tj~



The term "halogen" means fluorine, chlorine,
bromine and iodine.
The term "alkylthio" means an alkylthio sub~ti-
tuted with the above alkyl group.
The term "alkylsulfonyl" means an alkylsulfonyl
substituted with the above alkyl group~
- The term "lower alkyl" in Xl or X2 meanR a lower
alkyl having 1 to 6 carbon atoms as stated above.
The term "cinnamoyl" means unsubstituted and subs-

tituted at a a position or a phenyl ring with one or moreof the same or different substituents selected from the
groups as described,such as p-methylcinnamoyl, p-methoxy-
cinnamoyl, a-phenylcinnamoyl, m-nitrocinnamoyl, 3,4-
methylenedioxycinnamoyl, p-formylcinnamoyl~ m-trifluorometh~l-
cinnamoyl, p-chlorocinnamoyl, p-aminocinnamoyl, p-hydroxy-
cinnamoyl, o-carboxycinnamoyl, ~methylcinnamoyl, -fluoro-
cinnamoyl, a-cyano-p hydroxycinnamoyl, 2,6 dichlorocinnamoyl 9
2,5-dimethoxycinnamoyl, ~,4-dimethylcinnamoyl, 4-hydroxy-~-
methoxycinnamoylj 3,4-dihydroxycinnamoyl, 2,4,5-trimethyoxy-
cinnamoyl, 3,5-dimethoxy-4-hydroxycinnamoyl and the like~
The compound of the formula (I) of the preqent
invention can be prepared by reacting 4-carbamoyllmidazolium-
5-olate (II)

- C - ~H
2 .. -~ ,
~O '' ~ (II)
H

or it~ reactive derivative with a carboxylic acid of the
formula (III);
R ~ OH (III)
wherein R i~ as defined above or its reactive derivative.
-- 6 --

5~



Example~ of preferred reactive derivatives of
carboxylic acids of the formula (III) are carboxylic acid
halides (e.g. chlorides, bromides, iodides, fluorides),
carboxylic acid anhydrides, mixed anhydrides (e.g. mixed
anhydrides with ethyl chloroformate, isobutyl chloroformate
and the like), activated esters (e.g. p-nitrophenyl e~ter,
ester with ~hydroxysuccinimide), imidazolide (e.g. pre-
pared by reacting N,N'-carbonyldiimidazole with a carboxylic
acid~(III)), activated intermediates prepared by reacting
a carboxylic acid (III) with reaction products obtained
from N,N-dimethylformamide and oxal~l chloride (or phosgene
or thionyl chloride or phosphorus pentachloride) and the
.
like.
Examples of preferred reactive derivative~ of
4-carbamoylimidazolium-5-olate of the formula (II) are
trimethylsilyl derivatives, trialkyltin derivatives ? mer-
cury salts, silver salts and the like.
Typical examples of preferred solvents which may
be used in this reaction are methylene chloride, chloroform,
pyridine, diethyl ether, tetrahydrofuran, dioxane, benzene,
toluene, methanol, ethanol, N,N-dimethylformamide, formamide,
N,N-dimethylacetamide, acetonitrile, nitromethane, acetone,
ethyl acetate, dimethylsulfoxide, dichloromethane, dichloro-
ethane, xylene and water.
~ he reaction can generally be effected at a reaction
temperature from -78 to 100C.. preferably from 60 to
60C.
The reaction of 4-carbamoylimidazolium-5-olate
with said carboxylic acid halides
can usually be carried out in an inert polar solvent or




a mixture of water and inert organic solvent, preferably
in the presence of an inorganic or organic base, at a tem-
perature from -10 to 60C. using one to two mole equiva-
lent~ of the acid halide.
Typical examples of said inert polar solvent
are tetrahydrofuran, dioxane, pyridine~ N,N-dimethylform-
amide, formamide, N,N-dimethylacetamide and dimethylsulfoxide.
Typical examples of said inert organic solvents are tetra-
hydrofuran, dioxane, diethyl ether, chloroform, dichloro-
methane, dichloroethane, benzene, toluene, and xylene.Examples of preferred inorganic base are sodium hydroxide 9
sodlum carbonate, sodium bicarbonate, potassium carbonate
or bicarbonate and potassium hydroxide. Examples of pre-
ferred organic base-are pyridine, triethylamine and N,~-
dimethylaniline.
The reaction of 4-carbamoylimidazolium-5-olate
with the activated intermediates prepared by reacting a car-
boxylic acid (III~ with reactlon products obtained from
N,N-dimethylformamide and oxalyl chloride (or phosgene or
~0 thlonyl chloride or pho~phorus pentachloride) can usually
be carried out in an organic solvent (e.g. acetonitrile,
pyridine, N,N-dimethylformamide, ~T,~-dimethylacetamide,
chloroform) at a temperature from -78 to 80C.
The compounds of the formula (I) can also be pre-
pared by reacting a silylated derivative of 4-carbarnoyl-
imidazolium-5-olate with reactive derivatives of a carboxyllc
acid (III) (e.g. acid halide~) at a temperature from -78
to 50C. in an inert organic ~olvent (e.g. dimethylformamide,
tetrahydrofuran, dioxane, diethyl ether, benzene, toluene).

s~



The silylated derivatives of 4-carbamoylimida-
zolium-5-olate are known and can be prepared by known
methods (Hayashi, et al. Japanese Patent Publication
(Kokai) No. 50-121276). When -the compounds of the ~ormula
~I) exist in the form of their silylated derivative in the
reaction mixture, the compound (I) can be obtained by
desilylation reaction with desilylating reagents (e.g.
acetic acid, methanol).
When reactive derivative of acid (III) is the
acid halide, the eliminated halide can be neutralized by an
organic base (e.g. triethylamine, pyridine).
The compounds of the formula (I) substituted with
an amino, hydroxy and carboxyl group can be prepared by
the said acylation methods after protecting an amino,
hydroxy and carboxyl group with protective groups (e.g.
benzyl, benzyloxycarbonyl, t-butox~carbonyl and the like)
and by removing protective groups.
The compounds of the formula (I) can be isolated
and purified by known purification methods (e.g. recrystal-
lization, column chromatography).
The compounds of the formula (I) may form a salt
with an inorganic acid (e.g. hydrochloric acid, sulfuric acid,
nitric acid, phosphoric acid) or an organic acid (e.g. p- -
toluenesulfonic acid, benzenesulfonic acid, methanesulfonic
acid, tartaric acid, malic acid, lactic acid, maleic acid,
fumaric acid.
The imidazole derivatives of the present inven-
tion may exist in a mixture of the two tautomers as follows:




o o
n - n

RO ~ N~ 1~ N - C ~Q N

both of which are within the scope of the present invention~
The cDmpounds of the present invention po3sess
potent antitumor activities against Sarcoma 180, ~ewi3
lung carcinoma, ~hrlich carcinoma, P-~88 leukemia and the
like~ The compounds of the formula (I) are useful a~ -anti-
tumor agents, and they exhibit par-ticularly excellent
inhibitory effects against tumor and also exhibit a pro-
longing ef~ect on the life span.
~he antitumor activitie~ of the compounds of the
present invention were estimated according to the methods
described in "Cancer chemotheraphy reports" Part 3, Vol. 3,
(~o. 2) p.l3 (1972). The results are given in the following
- Table 1.
Table 1 Antitumor effect on
mouse experimental
tumor~
Inhibition
Do~e Ratio ~%)
Compound~ (mg/kg)Sche~
Route ~.p. carcinoma
(solid~

5-Carbamoyl-lH-imidazole-
4-yl p-phenylbenzoate 1005q2d 77.0
5-Carbamoyl-lH-imidazole- d 0
4-yl p-chlorocinnamate .1005q2 9
5-Carbamoyl-l~-imidazole- 10
4-yl m-nitrocinnamate 5q2d 90


-- 10 --

-




Table 1 (cont7d)

5-Carbamoyl-lH-imidazole-
4-yl 3',4'~dimethoxy- 100 5q2d ~3.1
benzoate
5-Carbamoyl-l~-imidazole-
4-yl 3'-methoxy-4'- 100 5q2d 89.4
methylbenzoate

BDFl male mice, 5 weeks old, weighing between
18 and 22 grams were used. ~ach test group was composed
of 6 to 7 mice. ~wo million cells of ~ewis lung carcinoma
were injected in the hind leg. The drug was administered
intraperitoneally at day 1, 3, 5, 7 and 9 (or 5q2d).
After killing the mice at day 13, tumors were
removed and weighed. ~he tumor inhibitory ratio was cal-
- culated according -to the following formula.
the mean tumor weights
Inhibition ratiO = (1 _ f treated ~roup ) x 100
the mean tumor weights
of control group

The compounds of the present invention also
possess excellent immunosuppressive activity as well as
potent antitumor activity.
~ he compounds (I) of the present invention have
low toxicity. ~hey do not show any toxic syrnptoms -even whe~
over 1000 mg/kg of the compounds are orally administered
to a mouse. Moreover, they do not exhibit the influence of
decreasing of peripheral leucocytes, which is one of the
most serious side effects of imml~osuppress~nts.
The compounds of the present invention can be
administered orally or parenterally to a warm-blood animal
at a daily dose of 2 - 200 mg/kg as an antit~nor agent, and
1 - 100 mg/kg as an immunosuppressant agent in a conventional

-- 11 --

;2~



dosage unit form.
The compounds of the present invention may be
made up alone or together with a conventional pharmaceu-
tical carrier or diluent into a conventional solid or
liquid pharmaceutical preparation (e.g. powders, granule~,
tablets, capsule~,`suspensions, emulsions, solutions) using
the conventional methods in the pharmaceuticai field.
For example, tablets or capsules may contain 50 - 500 mg
of the compounds (I).
Especially, the compounds (I~ of the present
invention can be used for oral administration and are effec-
tive for a long period.
The following examples are given to illustrate
the present inve~tion more precisely but i-t is not intended
to limit the present invention -thereto.

Example
To a suspension of 0.636 g. of 4-carbamoylimida-
zolium-5-olate in 15 ml of dry pyridine was dropwisely
added 1.2 g of 2,6-dimethylbenzoyl chloride at a temperature
below 5C. in N2 atmosphere. After being stirred for two
hours at 41 - 43C., the reaction mixture was cooled to room
temperature and a 0.8 g of triethylamine was added, and
separated crystals were filtered off. ~hen the filtrate
was concentrated under reduced pressure, and separated
crystals were filtered off, washed with toluene and ether
and dried to give 0.689 g of 5-carbamoyl-lH-imidazole-4-yl
2',6'-dimethylbenzoate, m.p. 176 - 177C~
Crude material was recrystallized from N,N-dime-thyl-
formamide and water. m.p~: 180 - 180.5C.

- 12 -

2-39




~nujol
~ max (cm 1): 3425, 3160, 1725, 1670, 1610
Elemental analysis: C(%) H (%) ~(%)
Calculated for C13H13N~3 0 3H20 59.00 5.18 15.88
Found 59.1 5.0 15.6


Example 2
Following a procedure similar to that of Example 1
but using 0.636 g of 4 carbamoylimidazolium-5-olate and
1.30 g of 3,4-dimethoxybenzoyl chloride there was obtained
1.353 g of 5-carbamoyl-lH imidazole-4-yl 3',4'-dimethoxy-
benzoate. m.p.: 209.5C. (dec~)
Crude material was recrystallized ~rom ~,N-di-

methylformamide and water. m.p.: 216.5C.


~ max (cm ): 3440, 3330, 3120, 1750, 1650, 1590
Elemental analysis: C(%) H(%) N(~)
Calculated for C13H13N305 53.61 4.50 14.43
Found 53.38 4.43 14.30


Example 3
Following a procedure similar to that of Example 1but using 0.636 g of 4-carbamoylimidazolium-5-olate and
2.0 g of 2,4,6-trimethoxybenzoyl chloride there was obtained

0.699 g of 5-carbamoyl-lH-imidazole-4-yl 2',4',6'-trime-thoxy- -
benzoate. m.p.: 174C. (charred)
Crude material was recrystallized from N,N-dimethyl-

formamide and water. m.p.: 184.5C. (charred)



~ max (cm 1): 34109 3330, 1750, 1670, 1610, 1590
Elemental analysis: C(~) H(%) N(~)
Calculated for C14~15N~06 52.34 4.71 13.08
Found 52.2 4.8 13.2

-- 1~ --

59



Example 4
Following a procedure similar to that of Example 1but using 0.508 g of 4-carbamoylimidazolium-5-olate and
1.83 g of 3,4-bisbenzyloxybenzoyl chloride there wa~
obtained 1.548 g of 5-carb~noyl-lH-imidazole-4-yl 3'~4'-
bisbenzyloxybenzoate. m.p.: 189.5 - 191.5C.
Crude material was recrystallized from N,N-dimethyl-
formamide and water. m.p.: 191.5 - 192.5C.
nujol
~ max (cm ): 3460, 3150, 1740, 1670, 1605
Elemental analysis: C(%) H(%) N~%)
CalcuIated for C25H2105N~ 67.71 4.77 9.48
Found ~ 67.4 4.9 9.3 5

~xam~le 5
A suspension of 0.55 g of 5-carbamoyl-lH-imidazole-
4-yl 3',4'-bisbenzyloxybenzoate and 0.3 g of 10 % Pd-C in
dry tetrahydrofuran was stirred for 6 hours at room tem-
perature in H2 atmosphere. Separated precipitates were
filtered off and the filtrate was concentrated under reduced
pressure to give 0.270 g of 5-carbamoyl-lH-imidazole-4-yl
3',4'-dihydroxybenzoate. m.p.: 156C. -- s
Crude material was recrystalli~ed from dimethyl-
sulfoxide and water. m.p.: 159 - 161C.
nujol
~ max ~cm~ ): 3480, 3225, 1735, 1675, 1600
Elemental analysis: C(%) H(%) N(~)
Calculated fo~ Cll~9N35 1 2~2 46.39 4.03 14.75
Found 46.46 3.81 14.45

- 14 -




Example 6
A mixture of 0.212 g of 3,5-dinitrobenzoic
acid, 0.127 g of 4-carbamoylimidazolium-5-olate and
0.206 g of dicyclohexylcarbodiimide in 4 ml of dry pyri-
dine was stirred for 21 hours at room temperature.
Separated precipitates were filtered off and were washed
with ethyl acetate to give 0.355 g of 5-carbamoyl-lH-
imidazole-4-yl 3'~5'-dinitrobenzoate which was recrystallized
from dimethylsulfoxide and water. m.p.: 220C. (decomp.)
Elemental analysis: C(~0) H~o) N(~)
Calculated for CllH7N507 41.13 2.20 21.81
Found 41.5 2.4 20.9

Example 7
Following a procedure similar to that of Example 6
but using 0.83 g of 3-methoxy-4-methylbenzoic acid, 1.03 g
of dicyclohexylcarbodiimide and 0.635 g of 4-carb~noyl-
imidazolium-5-olate there was obtained 1.45 g of 5-carbamoyl-
lH-imidazole-4-yl 3'-methoxy-4'-methylbenzoate.
Crude material was recrystallized from N,N-dimethyl-
formamide and water. m.p.: 210C. (decomp.)

nujol (cm 1): 3450, 1740, 1655, 1600max

~x~m~le 8
A mixture of 76.26 g of 4-carbamoylimidazolium-
5-olate, 174.31 g of 1 J 1,1,3,3,3-hex~nethyldisilazane,
1.59 g of ammonium sulfate and 500 g of dry xylene was
refluxed for 4 hours. ~he reaction mixture was concentrated
under reduced pressure and a tris-trimethylsilylated deriya-
tive of 4-carbamoylimidazolium-5-olate was obtained.

- 15 ~

i2~



m.p.: 83 - 86.5C.
To a stirred solution of 1.718 g of tris-tri-
methylsilylated derivative of 4-carbamoyl-imidazolium~5-
olate in 15 ml of dry tetrahydrofuran was dropwisely added
a solution o~ 0.833 g of cinnamoyl chloride in 5 ml of
dry tetrahydrofuran at -50C. under N2 atmosphere. After
being stirred for half an hour at -50C., 0.32 g of dry
methanol was added to the reaction mixture. After being
stirred for 15 minutes at -50C. t 0.51 g of triethylamine
was added.
The reaction mixture was heated up to room tempera-
ture and then separated crystals were filtered off, washed
with tetrahydrofuran and chloroform and dried to give
0.796 g of 5-carbamoyl-lH-imidazole-4-yl cinnamate.
m.p.: 170 - 175C. The filtrate of a tetrahydrofuran
solution was concentrated and diethylether was added to
the residue and separated crystals were filtered of~,
washed with diethyl ether and dried to give 0.427 g of
said product.
Crude material was recrystallised from dimethyl-
sulfoxide and water. m.p. 197C. (charred~
~nujol
~ max (cm ): 3460, 3160, 3110, 1720, 1670, 1605
Elemental analysis: ~(%) H(%) N(~)
Calculated for C13EllN33 O-lH~0 60.27 4.36 16.22
~ound 60.1. 4.4 16.3

Ex~nple _
~ ollowing a procedure similar to that of Example
8 but using 0.9 g of p-methylcinnamoyl chloride there was
obtained 1.270 g o~ 5-carbamoyl-lH imidazole-4-yl p-methyl-


S9



cinnamate. m.p.: 171C. (decomp.)
Crude material was recrystallized from dimethyl-
sulfoxide and water. m O p. 194C. (charred)

nujol (cm~l): 3440, 3150, 1715, 1665, 1600
max
~lemental analysis: C(%) H(~) N(%)
Calculated for C14H13~33 2H2 15.29
Found 61.19 4.69 15.49

~xample 10
Following a procedure similar to that of Example
8 but using 1.01 g of p-chlorocinnamoyl chloride there was
obtained 1.408 g of 5-carbamoyl-lH-imidazole-4-yl p-chloro-
cinnamate. m.p. 172C. (dec.)
Crude material was recrystallized from dimethyl-
sulfoxide and water. m.p.: 202C~ (dec~)
nu;ol
~ max (cm ): 3440, 3380, 3150, 1725, 1660l 1615
Elemental anlaysis: C(~) H(%) N(%)
Calculated for C13HlON303Cl 0 1~20 53.20 3.5 14.32
Found 53.1 3.8 14.1

Example 11
Following a procedure similar to that of Example
8 but using 1.053 g of 3,4-methylenedioxycinnamoyl chloride
there was obtained 1.172 g of 5-carbamoyl-lH-imidazole-4-yl
3',4'-methylenedioxycinnamate. m.p.: 165 - 175C.
Crude material was recrystallized from dimethyl
sulfoxide and water. m.p.: 189C. (char.)

max (cm~l): 3460, 3400, 3125, 1735, 1670, 1630, 1605

~ 17 -





Elemental analysis: C(%) H(/J0) ~(%)
Calculated for C14Hl~T35 0 4H20 54.51 3.86 13.62
Found 54.49 3.71 13.48


ExamPle 12
Follwing a procedure similar to that of Example 8
but using 0.98 g of p-methoxyeinnamoyl chloride, there was
obtained 1.15 g of 5-carbamoyl-lH-imidazole-4-yl p-methoxy-
einnamate. m.p.: 165 - 167C. (dee.)
Crude material was reerystallized from dimethyl-

sulfoxide and water. m.p.: 185C. (ehar.)

nujolmax (em~ ): 3470, 3175, 1725, 1670, 1605
~lemental analysis: C(%) H(%) ~(%)
Caleulated for C14H13N34 6H2 56.41 4.80 14.10
Found 56.75 4.63 13.85

.. . ... . . .
Example 13
Following a procedure similar to that of ~xample 8
but using 0.97 g of p-formyleinnamoyl chloride, there was
obtained 1.086 g of 5-carbamoyl-lH-imidazole-4-yl p-formyl-
einnamate.
Crude material was recrystallized from dimethyl-
sulfoxide and water. m.p.: 233C~ (ehar.)



max (em 1): 3100~ 1730, 1680, 1650, 1620, 1590

~lemental analysis: C(~o) H(%) N(~o)
Caleulated for C14HllN34 0'5H2 14.28
Found 57.0 3.9 14.0




- 18 -

3~



Example 14
Following a procedure similar to that of Example 8
but using 1.173 g of m-trifluoromethylcinnamoyl chloride,
there was obtained 1.236 g of 5 carbamoyl-lH-imidazole
4-yl m-trifluoromethylcinnamate. m.p.: 167 - 170C. (dec.)
Crude material was recrystallized from dimethyl-
sulfoxide and water. m.p.: 188C. (char.)
nujol
~ max (cm ): 3460, 3175, 1730, 1680, 1610
Elemental analysis: C(~) H(~) N(%)
Calculated for C14HloN303F3 2 51.42 3.14 12.85
Found 51.19 2O98 13.09

EY.ample 15
Following a procedure similar to that of Example 8but using 1~058 g of m-nitrocinnamoyl chloride, there was
obtained 1.383 g of 5-carbamoyl-lH-imidazole-4-yl m-nitro-
cinnamate.
Crude material was recrystallized from dimethyl-
sulfoxide and water. m.p.: 197C, ~char.)
nujol
~ max (cm ): 3450, 3120, 1740, 1650, 1600
~lemental analysis: C(%) H(~) N(%3
Calculated for C13HloN405 0-3H2 18.21
Found 50.76 3.30 18.20

Example 16
Following a procedure similar to that of Example 1
but using 1.46 g of a-phenylcinnamoyl chloride, there was
obtained 1.186 g of 5-carbamoyl-lH-imidazole-4-yl a-phenyl-
cinnamate. m.p.: 208C.

- 19 -
.




Crude material was recrystallized from dimethyl-
sulfoxide and water. m.p.: 212C.



~ max (ck 1): 3450, 3125, 1735, 1655, 1605
Elemental analysis: C(~) H(%)
Calculated for ClgH15~303 0 3H20 67.37 4.64 12.40
Found 67.48 4.51 12.41


xample 17
. Following a procedure similar to that of ~xample 1
but using 2.544 g of 4-carbamoylimidazolium-5-olate and

5.922 g of p-benzyloxybenzoyl chloride, there was obtained
5-carbamoyl-lH-imidazole-4-yl p-benz~loxybenzoate.
Crude material was recrystallized from dimethyl-
sulfoxide and water. m.p.: 215 - 218C. (dec.)

~ nu~ol ( -1) 1730 16~0


Elemental analysis: C(~)H(%) N(%)
Calculated for C18H1504~3 64.09 4.48 12.46
Found 63.5 4.5 12.3


Exam~le 18
Following a procedure similar to that of ~xample 1

but using m-trifluoromethylbenzoyl chloride, there was
obtained 5-carbamoyl-lH-imidazole-4-yl m-trifluoromethyl-
benzoate. m.p. 208 - 211C. (dec.)

~ nu a ol ( cm~l): 1730 1670


Elemental analysi~: C(~)H(%) N(~)
Calculated for C12H80~N3F3 48.17 2.7 14.04
Found 48.0 2.9 14.0

-- ~0 --

5~



~xam~le 19
Following a procedure similar to that of Example 1
but using p-N-benzyloxycarbonylaminobenzoyl chloride,
there was obtained 5-carbamoyl-lH-imidazole-4-yl p-N-
benzyloxycarbonylaminobenzoate. m.p.: 187 - 190C. (dec.)

nujol
~ max (cm ): 1730, 1680, 1660
Elemental Analysis: C(%) ~(%) N(~)
Calculated for cl9Hl6o5N4 59.99 4.24 14.73
Found 59.6 4.3 14.5


Example 20
Eollowing a procedure similar to that of Example 1
but using 1.41 g of 4-biphenylcarbonyl chloride, there was
obtained 1.33 g of 5-carbamoyl-lH-imidazole-4-yl p-henyl-
benzoate. m.p.: 225C. (char.)
Crude material was recrystallized from N,N-dime-thyl-

formamide and water. m.p~: 226.5 - 227C. (char~)

nujol
~ max (cm 1): 3460, 3160, 1735, 1675, 1605
Elemental analysi~: C(%) H(~
Calculated for C17H1~303 66.44 4.26 13.67

~ound 66.6 4.3 13.5



ExamPle 21
~ ollowing a procedure similar to that of Example 8
but using 1.1 g of o-acetylsalicyloyl chloride, there was
obtained 1.29 g of 5-carbamoyl~ imidazole-4-yl o-acetoxy-
benzoate. m.p.: 143-145C.

nujol
max (cm ~ 430, 3190, 1755, 1670, 1605

21 -

2S~



Example 22
~ o a stirred solution of 6.3 ml of N,~T-dimethyl
formamide in 14 ml of acetonitrile was added slowly 0.45 ml
of oxalyl chloride a-t -20C. and the reaction mixture
was heated up to room temperature. ~o the reaction mixture
was added 1.33 g of o-benzyloxycarbonylbenzoic acid at
-25C. and the reaction mixture was heated up to room tem-
perature. lo the reaction mixture were added 0.636 g of 4-
carbamoylimidazolium-5-olate and 2.5 ml of dry pyridine
over ice bath in ~2 atmosphere and stirring was continued
~or 30 minutes at room temperature.
~ o the residue was added 1.9 ml of triethylamine
over ice bath and separated precipitates were filtered off
and the filtrate was concentrated under reduced pressure
to give 0.78 g of 5-carbamoyl-lH-imidazole-4-yl o-benzyloxy-
carbonylbenzoate. m.p.: 122 - 124C.

nujol
max (cm~l~: 3460, ~150, 1770, 1725, 1670, 1610

Example 23
Following a procedure similar to that of ~xample 1
but using 1.19 g of p-methoxycarbonylbenzoyl chloride, there
was obtained 1.4 g of 5-carbamoyl-lH-imidazole-4-yl p-
methoxycarbonylbenzoate 4
Crude material was recrys-tallized from dirnethyl-
sulfoxide and water. m.p.: 215C. (dec.) '

nujol
max (cm 1): 3475, 3440, 3180, 3120, 1750, 1735,
1680, 1605




~lemental analysis: C(%) H(%) N(%)
Calculated for C13HllN305 53.98 3.83 14.53
~ound 5~.4~ 3.80 14.46

According to the present invention, there are
obtained, for example, the following compounds:
5-carbamoyl-lH-imidazole-4-yl p-aminocinnamate,
5-carbamoyl-lH-imidazole-4-yl p-hydroxycinnamate,
5-carbamoyl-lH-imidazole-4-yl o-carboxycinnamate,
5-carbamoyl-lH-imidazole-4-yl a-cyano-4'-hydroxycinnamate,
5-carbamoyl-lH-imidazole-4-yl 3',4'-dichlorocinnamate,
5-carbamoyl-lH-imldazole-4~yl 3',4'-dimethpxycinnamate,
. . 5-carbamoyl-lH-imidazole-4-yl 3',4'-dimethylcinnamate,
5-carbamoyl-lH-imidazole-4-yl 4'-hydroxy-3'-methoxycinnamate,
5-carbamoyl-lH-imidazole-4-yl 3',4',5'-trimethoxycinnamate,
5-carbamoyl-lH-imidazole-4-yl 3',4'-dihydroxycinnamate,
5-carbamoyl-lH-imidazole-4-yl a-~luorocinnamate~
5-carbamoyl-lH-imidazole-4-yl 3',5'-dimethoxy-4'-hydroxycinnamate,
5-carbamoyl-lH-imidazole-4-yl a-methylcinnamate,
5-carbamoyl-lH-imidazole-4-yl p-octylcinnamate,
5-carbamoyl-lH-imidazole-4-yl p-dodecylcinnamate,
5-carbamoyl-lH-imidazole-4-yl p-doco~ylcinnamate,
5-carbamoyl-lH-imidazole-4-yl p-ootyloxycinnamate,
5-carbamoyl-lH-imidazole-4-yl p-octadecyloxycinnamate, ~ .
5-carbamoyl-lH-imidazole-4-yl pentafluorobenzoate,
5-carbamoyl-lH-imidazole-4-yl 2',4'-dicarboxybenzoate,
5-carbamoyl-lH-imidazole-4-yl ~'-amino-4'-mbthylbenzoate,
5-carbamoyl-lH-imidazole-4-yl 3'-acetyloxy-4'-methylbenzoate,
5-carbamoyl-lH-imidazole-4-yl 2'-benzyloxy-5'-methylthiobenzoate,
5-carbamoyl-lH-imidazole-4-yl 4'-methylsulfonyl-3'-nitrobenzoate,

- 23 -

z~


5-carbamoyl-lH-imidazole-4-yl 4'-chloro-3'-sulfamoylbenzoate,
5-carbamoyl-lH~imidazole-4-yl 2'-hydroxy-5'-methylthiobenzoate,
5-carbamoyl-lH-imidazole-4-yl 51-~ormyl-2'-hydroxybenzoate,
5-carbamoyl-lH-imidazole-4-yl 2 7 -hydroxy-5'-sulfobenzoate,
5-carbamoyl-lH-imidazole-4-yl 4'-diethylamino-2'-hydroxybenzoate,
5-carbamoyl-lH-imidazole-4-yl 4'-methyl-3'-octyloxybenzoate 9
5-carbamoyl-lH-imîdazole-4-yl 4'-methyl-3'-octodecyloxybenzoate,
5-carbamoyl-lH-imidazole-4-yl 3'-methoxy-4'-lauroyloxybenzoate,
5-carbamoyl-lH-imidazole-4-yl ~1-methoxy-4'-stearoyloxybenzoate,
5-carbamoyl-lH-imidazole-4-yl 4'-hexadecyl-2i-methylbenzoate,
5-carbamoyl-lH-imidazole-4-yl 2'-dodecyl-4'-methoxybenzoate,
5-carbamoyl-lH-imidazole-4-yl p-aminobenzoate,
5-carbamoyl-lH-imidazole-4-yl p-hydroxybenzoate,
5-carbamoyl-lH-imidazole-4-yl o-benzoylbenzoate,
5-carbamoyl-lH-imidazole-4-yl o-carboxybenzoate,
5-carbamoyl-lH-imidazole-4-yl o-phenoxybenzoate,
5-carbamoyl-lH-imidazole-4-yl p-formylbenzoate,
5~carbamoyl-lH-imidazole-4-yl p-acetylbenzoate,
5-carbamoyl-lH-imidazole-4-yl p-carbamoylbenzoate,
5-carbamoyl-lE-imidazole-4-yl p-octanoylbenzoate,
5-carbamoyl-lH-imidazole-4-yl p-palmitoylbenzoate,
5-carbamoyl-lH-imidazole-~ yl p-octyloxycarbonylbenzoate,
5-carbamoyl-1~-imidazole-4-yl p-octadecyloxycarbonylbenzoate,~
5-carbamoyl-lE-imidazole-4-yl p-octanoyloxybenzoate,
5-carbamoyl-lH-imidazole-4-yl p-palmitoyloxybenzoate.




- 24 -

Representative Drawing

Sorry, the representative drawing for patent document number 1166259 was not found.

Administrative Status

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Administrative Status , Maintenance Fee  and Payment History  should be consulted.

Administrative Status

Title Date
Forecasted Issue Date 1984-04-24
(22) Filed 1981-09-23
(45) Issued 1984-04-24
Expired 2001-04-24

Abandonment History

There is no abandonment history.

Payment History

Fee Type Anniversary Year Due Date Amount Paid Paid Date
Application Fee $0.00 1981-09-23
Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
SUMITOMO CHEMICAL COMPANY, LIMITED
Past Owners on Record
None
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Drawings 1993-12-07 1 14
Claims 1993-12-07 9 310
Abstract 1993-12-07 2 38
Cover Page 1993-12-07 1 21
Description 1993-12-07 22 821